Designing Longevity
Skip to main content
Emerging ResearchPeptide

FOXO4-DRI

The senolytic peptide

Senolytic Peptide (FOXO4-p53 disruptor)

Last updated: August 2026
Share:

Evidence Level: Emerging Research

Very new, early-stage research, high uncertainty

Regulatory Status: Not approved anywhere and not in clinical development that has been publicly reported. Sold as a "research chemical."

FOXO4-DRI is a designed peptide that kills by breaking a specific protein interaction they depend on to stay alive. A 2017 paper in Cell showed it improved fur density, kidney function, and physical activity in naturally aged mice. It is one of the most cited results in aging biology, and nearly a decade later no human trial has been run.

How It Works

This is one of the most elegant pieces of drug design in aging research, which is part of why the absence of human data is so conspicuous.

What are. When a cell is damaged beyond repair but does not die, it can enter : alive, no longer dividing, and secreting a stream of inflammatory signals that damage the tissue around it. These are the "zombie cells" you see referenced in longevity writing. They accumulate with age and contribute to chronic inflammation, tissue dysfunction, and multiple age-related diseases. Clearing them in mice improves healthspan.

The vulnerability the researchers found. should die by , the normal cellular self-destruct program, and the protein that would normally trigger it is p53. Researchers at Erasmus University Medical Center found that senescent cells survive by producing large amounts of a protein called FOXO4, which grabs p53 and holds it in the cell nucleus where it cannot execute the death program.

So are not invulnerable. They are holding a hostage.

The design. FOXO4-DRI is a fragment of FOXO4 built as a D-retro-inverso peptide, meaning it uses mirror-image amino acids in reverse order. That construction makes it resistant to the enzymes that would normally break down a peptide while preserving the shape needed to bind p53. It competes with the cell's own FOXO4 for p53, releases p53, and lets proceed.

The selectivity follows naturally: healthy cells do not depend on the FOXO4-p53 interaction to survive, so releasing p53 in them does nothing. Only cells relying on that hostage arrangement die.

What happened in mice. In the 2017 Cell paper, treatment of naturally aged mice restored fur density, improved kidney function, and increased physical activity. It also accelerated recovery from doxorubicin chemotherapy toxicity. The typical regimen was 5mg/kg intraperitoneally, three times weekly. Those are striking results in an aging model.

And then, effectively, nothing. Nearly a decade later there is no published human trial, no publicly reported investigational new drug program, and no phase 1 safety data. That silence is informative. Peptide drug development is hard: D-retro-inverso peptides are expensive to make at scale, distribution to tissues is difficult, and the safety profile of systemically triggering in a human is a serious question. Meanwhile, the field has largely moved toward small molecules like dasatinib plus quercetin and fisetin, which are cheap, orally available, and already in human trials.

The mouse result is real. The translation has not happened.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Longevity biomarkersPreclinical certainty

Selectively kills senescent cells and improves healthspan measures.

Population: No human population has been studied. Evidence is from naturally aged mice and human cells in culture.

Why this rating

The mechanism is well characterized and the mouse evidence is strong, published in Cell, and supported by work showing the mechanism operates in human cells in culture. But there has never been a human trial of any kind, including phase 1 safety, and there is no published human pharmacokinetic data. Nine years after the landmark paper with no clinical program is itself a meaningful signal about translation difficulty.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • Exceptionally elegant and well-characterized mechanism targeting a specific vulnerability in
  • Published in Cell, one of the highest-profile journals in biology, and heavily cited
  • Improved multiple healthspan measures in naturally aged mice, including kidney function and physical activity
  • Accelerated recovery from chemotherapy toxicity in mouse models
  • Selective by design: healthy cells do not depend on the interaction it disrupts
  • The D-retro-inverso construction genuinely solves the peptide stability problem

Risks & Considerations

  • Zero human clinical trials of any kind, including phase 1 safety, nearly a decade after the landmark paper
  • No published human pharmacokinetic data, so nobody knows whether an injected dose reaches at all
  • Triggering systemically is a serious safety question that has never been assessed in a person
  • p53 biology is central to cancer, and manipulating it has consequences nobody has characterized in humans
  • Mouse dosing (5mg/kg three times weekly) does not translate to humans, and the peptide is expensive to synthesize
  • The field has largely moved to small-molecule , which suggests developers see translation problems here
  • Extremely expensive on the gray market for a compound with no human data

Dosing Information

There is no human dose. No human study has ever been conducted. The mouse regimen is listed for reference only.

  • •Mouse studies used 5mg/kg intraperitoneally, three times weekly
  • •Body-weight scaling from mice to humans is not valid for peptides, and would imply doses that are prohibitively expensive anyway
  • •No published human pharmacokinetic, distribution, or safety data exists
  • •We are not publishing a protocol for a compound that has never been given to a human under study conditions

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1If interest you, dasatinib plus quercetin and fisetin are the compounds actually in human trials. Read our senolytics guide
  • 2Be wary of the price. FOXO4-DRI is among the most expensive research peptides sold, for a compound with zero human data
  • 3The strength of the mouse result is exactly why the absence of human follow-up over nine years is worth noticing
  • 4 generally are intermittently dosed rather than taken continuously, because do not reaccumulate quickly
  • 5If you have a cancer history, the p53 manipulation question is not theoretical enough to ignore

Key Research

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Cell, 2017

The landmark paper. FOXO4-DRI selectively killed senescent cells by disrupting the FOXO4-p53 interaction. In naturally aged mice it restored fur density, improved kidney function, and increased physical activity, and it accelerated recovery from doxorubicin toxicity.

View Study

Senolytic peptide FOXO4-DRI selectively removes senescent cells from expanded human chondrocytes

Frontiers in Bioengineering and Biotechnology, 2021

FOXO4-DRI selectively removed senescent cells from human cartilage cells expanded in culture, supporting that the mechanism operates in human cells.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has very early human evidence.

Frequently Asked Questions

Has FOXO4-DRI been tested in humans?

No. There have been no human clinical trials of any kind, including phase 1 safety studies, and no publicly reported investigational new drug program. The landmark mouse paper was published in Cell in 2017, and nearly a decade later the compound has not entered human testing. Everything claimed about its effects in people is extrapolation from mice.

How does FOXO4-DRI kill senescent cells?

stay alive by producing large amounts of a protein called FOXO4, which binds p53 and holds it in the nucleus where it cannot trigger the cell's self-destruct program. FOXO4-DRI is a designed fragment that competes for that binding, releases p53, and lets proceed. Healthy cells do not rely on that arrangement, which is why the effect is selective.

Why has no one run a human trial?

The published record does not say, but the practical obstacles are well known. D-retro-inverso peptides are expensive to manufacture at scale, getting a peptide distributed to throughout the body is difficult, and systemically triggering raises safety questions that require careful and costly work to answer. Meanwhile the field has largely moved toward small molecules like dasatinib, quercetin, and fisetin, which are cheap and orally available.

Is FOXO4-DRI better than dasatinib and quercetin?

In mice the FOXO4-DRI results are impressive, and its mechanism is more precisely targeted. But dasatinib plus quercetin has actually been given to humans in clinical trials for conditions including idiopathic pulmonary fibrosis and diabetic kidney disease. On the question of which one we know anything about in people, it is not close.

Is FOXO4-DRI safe?

Unknown, and the specific unknowns are not trivial. There is no human safety data at all. The mechanism involves releasing p53, a protein central to both cell death and cancer suppression, and deliberately triggering through a systemic drug in a human body has never been assessed for this compound. If you have a cancer history, this is a compound to discuss with an oncologist rather than a wellness clinic.

What are senescent cells and why clear them?

are damaged cells that stop dividing but refuse to die, and they secrete inflammatory signals that damage surrounding tissue. They accumulate with age and contribute to chronic inflammation and age-related disease. Clearing them in mice improves healthspan measures, which is why became one of the most active areas in aging research. Whether clearing them helps humans is still being tested.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Slow Aging Guide

Related Peptides

EpithalonPineal Tetrapeptide
MOTS-cMitochondrial-Derived Peptide

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: